Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rusfertide in beta-thalassemia (TRANSCEND)
NCT03802201Phase 2Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Dec 2018
- Primary completion
- Jul 2020
- Modality
- Peptides
- Countries
- 9
01
Overview
A Phase 2 trial of rusfertide in beta thalassemia, sponsored by Protagonist Therapeutics, Inc.. Started Dec 2018; status: completed.
02
Drugs
rusfertide
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT03802201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802201.